AUA2024 featured a wide range of content that is now available to be viewed on-demand thanks to educational grant support.
GU Cancers
Prostate Cancer
Overactive Bladder
Satellite Symposia
GU Cancers
|
Genetics and Genomics of Urological Cancers – Current Guidelines and Case-based Discussion to Guide Clinical Practice This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
AUA Advanced Prostate Cancer Guidelines This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
New AUA Guideline (2024): Salvage Therapy for Prostate Cancer This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Prostate Cancer Diagnosis: AUA Guidelines on use of PSA Biomarkers, MRI and Biopsy Techniques This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
The Changing Face of Advanced Prostate Cancer 2024 This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Upper tract urothelial cancer (UTUC) guidelines – an interactive and evidence-based course highlighting the full spectrum of disease via case discussion and video presentation This educational activity is supported by independent educational grants from: Merck & Co., Inc. |
|
Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management This educational activity is supported by independent educational grants from: Merck & Co., Inc., UroGen Pharma, Inc. |
|
Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems This educational activity is supported by an independent educational grant from: Merck & Co., Inc. |
|
Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Prostate Cancer?
|
|
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum
|
Prostate Cancer
|
Genetics and Genomics of Urological Cancers – Current Guidelines and Case-based Discussion to Guide Clinical Practice This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
AUA Advanced Prostate Cancer Guidelines This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
New AUA Guideline (2024): Salvage Therapy for Prostate Cancer This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Prostate Cancer Diagnosis: AUA Guidelines on use of PSA Biomarkers, MRI and Biopsy Techniques This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
The Changing Face of Advanced Prostate Cancer 2024 This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. |
|
Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Prostate Cancer?
|
|
Expanding Therapeutic Options in De Novo Metastatic Hormone-Sensitive Prostate Cancer: Overcoming Resistance to Traditional Therapies
|
Overactive Bladder
|
Contemporary Pharmacotherapy for OAB 2024: Monotherapy and Combined Pharmacotherapy to Optimize Treatment This educational activity is supported by an independent educational grant from: Astellas |
|
Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) This educational activity is supported by an independent educational grant from: Astellas |
Satellite Symposia
|
Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Prostate Cancer?
|
|
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum
|
|
Expanding Therapeutic Options in De Novo Metastatic Hormone-Sensitive Prostate Cancer: Overcoming Resistance to Traditional Therapies
|